Elicio Therapeutics (ELTX) Enterprise Value (2020 - 2026)
Elicio Therapeutics' (ELTX) quarterly Enterprise Value came in at -$14.9 million in Q1 2026, up 21.72% YoY from -$12.2 million in Q1 2025, and up 19.73% on a QoQ basis from -$18.6 million in Q4 2025.
Elicio Therapeutics (ELTX) Enterprise Value (2020 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has 7 years of Enterprise Value data on file, last reported at -$14.9 million in Q1 2026.
- Quarterly Enterprise Value rose 21.72% year-over-year to -$14.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$14.9 million (up 21.72% YoY) and the FY2025 annual result came in at -$18.6 million, up 1.24% from the prior year.
- Enterprise Value grew to -$14.9 million in Q1 2026, from -$18.6 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$598000.0 in Q2 2022 to a low of -$73.0 million in Q1 2022.
- A 5-year average of -$17.7 million and a median of -$16.5 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value surged 99.49% — and 2023, when it plunged 3525.75%.
- Tracing ELTX's Enterprise Value over 5 years: stood at -$7.8 million in 2022, then slumped by 74.63% to -$13.6 million in 2023, then tumbled by 38.04% to -$18.8 million in 2024, then grew by 1.24% to -$18.6 million in 2025, then grew by 19.73% to -$14.9 million in 2026.
- The last three Enterprise Value figures came in at -$14.9 million (Q1 2026), -$18.6 million (Q4 2025), and -$20.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Elicio Therapeutics | 59.08 Mn | 35.58 Mn | - | -23.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -23.50 Mn |
| Mar 31, 2026 | -14.90 Mn |
| Dec 31, 2025 | -18.56 Mn |
| Sep 30, 2025 | -20.61 Mn |
| Jun 30, 2025 | -22.09 Mn |
| Mar 31, 2025 | -19.03 Mn |
| Dec 31, 2024 | -18.80 Mn |
| Sep 30, 2024 | -27.33 Mn |
| Jun 30, 2024 | -3.82 Mn |
| Mar 31, 2024 | -12.55 Mn |
| Dec 31, 2023 | -13.62 Mn |
| Sep 30, 2023 | -16.54 Mn |
| Jun 30, 2023 | -21.68 Mn |
| Mar 31, 2023 | -8.57 Mn |
| Dec 31, 2022 | -7.80 Mn |
| Sep 30, 2022 | -1.84 Mn |
| Jun 30, 2022 | -598,000.00 |
| Mar 31, 2022 | -73.00 Mn |
| Dec 31, 2021 | -88.76 Mn |
| Sep 30, 2021 | -102.74 Mn |